In a recent public statement, Intrexon Corp (NYSE:XON) stated that the genetically engineered mosquito, which is used to get rid of Zika virus will have no significant impact on the global environment. The statement was inspired by U.S. Food And Drug Administration findings.
Insights of Matter
Intrexon, better known for its synthetic biology offerings, stated that scientists modify the males of Aedes aegypti mosquito in such a way that their offspring dies before they can reproduce. Its UK unit, Oxitec, developed this mosquito and submitted the draft study to authorities along with FDA approval.
Zika has affected and killed thousands of people from all across the globe over the past few months, raising concerns among medical science experts and prompting them to find a cure as soon as possible. The virus is carried by mosquitoes and can result in health issues like microcephaly and Guillain-Barre syndrome. The microcephaly is a birth defect while Guillain-Barre syndrome can cause paralysis to patients.
The Zika virus has been a talk of the time for last few months due to wrong reasons. Even though many organizations tried to come up with a cure to treat the diseases spread by Zika, most of them failed to come up with a permanent solution. Intrexon’s statement has come as a big relief at such a time. Moreover, FDA’s statement that the solution offered by Intrexon doesn’t put any adverse effect on environment has come as a morale booster for the investors.
As soon as Intrexon announced this news, its stock price increased 3% on Friday. The entire senior management team is delighted to witness this response from the shareholders and hopes that the company will continue to get such great results in the coming months as well. It looks forward to announcing many more such positive updates soon, details of which will be announced at a later date.
